Carmot Therapeutics, Inc.
409 Illinois Streeet
10 articles with Carmot Therapeutics, Inc.
Carmot Therapeutics announced today the initiation of a clinical trial for the treatment of type 2 diabetes with CT-868, a dual modulator of the GLP-1 and GIP incretin receptors.
Carmot announced today that it has closed a $15M financing.
12/12/2017Gilead was interested in Cell Design Labs for its technology around bi-specific antigen recognition and its "Throttle" technology.
Under the deal, Carmot will use its lead-identification technology to identify and advance novel drug leads for Parkinson's disease and other disease areas.
Carmot Therapeutics, Inc. Appoints Aetna Wun Trombley, Ph.D. To The Board Of Directors And Elena Viboch As Director Of Business Development And Operations